% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • blank2thisone blank2thisone Mar 31, 2014 2:30 PM Flag

    Q2 Roadmap

    ● Q2: Continued dialogue with EMA and FDA regarding NTM regulatory path
    ● Q2: First patient first visit in NTM open label study
    ● File eCTD for CF Pseudomonas with EMA
    ● Exact timing dependent on NTM data and EMA regulatory dialogue

    Sentiment: Strong Buy

24.35+0.32(+1.33%)Jul 6 4:00 PMEDT